This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tyrer, P. Articles by Seivewright, N. Search for Related Content PubMed Articles by Tyrer, P. Articles by Seivewright, N. Social Bookmarking                         What's this?

Clinical efficacy of paroxetine in resistant depression

Mapperley Hospital, Porchester Road, Nottingham NG3 6AA, UK

C.A. Marsden

Department of Physiology and Pharmacology, Medical School, Queen's Medical Centre, Nottingham NG7 2UH, UK

Patricia Casey

Mapperley Hospital, Porchester Road, Nottingham NG3 6AA, UK

N. Seivewright

Mapperley Hospital, Porchester Road, Nottingham NG3 6AA, UK

The antidepressant effects of a specific reuptake inhibitor of 5-hydroxytryptamine (5-HT), paroxetine, were tested in 24 patients with resistant depression who had failed to respond to conventional antidepressants after at least 4 weeks of treatment. A novel exper imental design was chosen in which all patients had 12 weeks of treatment beginning and ending with placebo therapy with 6 weeks of active drug treatment at some point in between. Ratings of depressive symptoms were made using the Hamilton rating scale (HRS) for depression, and the checklist for unwanted effects and their severity was also recorded before and during treatment at 2 week intervals. The change from placebo to active paroxetine therapy was made using a double-blind procedure. Patients who made a significant placebo response in the first 2 weeks of treatment were excluded from further analysis; 20 patients completed the study and satisfied all criteria for inclusion. Both groups of showed a significant improvement in symptoms after 4 weeks of paroxetine therapy. There were no significant treatment differences between the groups, but improvement in symptoms occurred sig nificantly later in the patients who had a longer period of initial placebo therapy. The experimental design also allowed study of withdrawal effects after stopping active treatment. There was no increase in adverse effects, including a subgroup associated with withdrawal problems, either during treatment with paroxetine or after the drug was stopped. The results suggest that paroxetine is probably an effective antidepressant, is well tolerated and has few adverse effects.

Journal of Psychopharmacology, Vol. 1, No. 4, 251-257 (1987)
DOI: 10.1177/026988118700100406


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. STIMPSON, N. AGRAWAL, and G. LEWIS Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression: Systematic review The British Journal of Psychiatry, October 1, 2002; 181(4): 284 - 294. [Abstract] [Full Text] [PDF]